Member Info for Sangijuelas1

Also the longer the patients are on the treatment the better. A perfect result would be all the 120 patients completing the maximum period possible of 2 years with positive responses. (Obviously not going to happen but the point is the more treatment cycles completed the better)

Michael as I posted yesterday the first part of the 0518 trial took 7 months from news of the first patient completing the first cycle to an interim update on how the trial was going in other patients. It is now 7 months since the February news on the first group of patients being dosed so news is likely anytime soon. Alex said 3 months ago to expect an update in late summer, early autumn. Not sure which part of this you are not getting.

I have also said before that it looks like because the more in depth analysis of the Blautix results showed greater efficacy than the initial overview 4D have changed their tone and it looks more like they want to run the P3 themselves without having to share the potential gains with a partner.

You can blame me when it goes tits up then BB

Have you seen this RNS about CAR-T potential? Wonder if we will get a licensing deal here like Tils?

https://www.4dpharmaplc.com/en/newsroom/press-releases/4d-pharma-publication-preclinical-oncology-research-LBP-improves-car-t

https://www.labiotech.eu/trends-news/car-t-cell-therapy-microbiome/

Since the Forte failure there has been a big seller. I do suspect it is our big US investor Steven Oliveira who may have been subject to a margin call.

He was one of the investors that stepped in when the former Woodford holding was being dumped by Acacia. If he is a forced seller this is effectively a firesale.

It's by far my biggest as well. I first invested in 2018 and there have been lots of ups and downs with the SP due to external factors like the Woodford fund problems and failures by other microbiome companies.

Meanwhile 4D has kept going from strength to strength. If you take the cash on hand everything they have is valued at only about £100m

So that's
-Micro RX platform for discovering the functionality of single bacterial strains.
-Blautix which is being prepared for a P3 pivotal trial.
-Partnerships with US Merck and also with German Merck/Pfizer to explore 0518 potential in oncology. If data positive on the former the high degree of unmet need in late stage cancer patients and inherent safety profile make it a strong candidate for Breakthrough Designation Therapy which would mean it could be brought to market much sooner.
-Also second generation oncology candidates, which amongst other things could deliver the holy gtail of CAR-T in solid tumours.
-And about to start Parkinsons trial and deliver initial data from the previously delayed Asthma trial.
-5% owned by US Merck. Listed on Nasdaq and now able to participate in prestigious investor events run by big US brokers like Oppenheimer and H c Wainwright.

Just looking back at the announcements of the Part A of the 0518 /Keytruda trial.
RNS April 2019 First patient completed Cycle 1 of the treatment.
Then 7 months later in November 2019 they gave an update and presented observations on the first 6 patients.

In February 2021 they said that 24 (of 120) patients on Part B had started the treatment and it is now 7 months later so expect something soon.

The news is not overdue. They said late summer early autumn. I believe we are still in late summer

Why are you invested here? Is it so you have something to whine about?

You said you would make a decision to sell at the beginning of September. What's it going to be?

The results are not overdue. Patient recruitment is not expected to end until December at the earliest.

What will be provided is an update on the early participants as it's an open label study and its all about time with 0518. The longer the patients are on 0518 and Keytruda the better. So data for 20 patients over 6 months worth more than for the same number over 3 months.

.

Part of what they are doing with the MRX platform is determining the actual functionality of strains like 0518.

It's a bit like the secret recipe for Coca-Cola as you could get a load of strains of E Gallinarum but you couldn't be sure you had the 0518 strain that generates a highly potent form of the anti tumour protein Flagellin unless you replicated the 4D research.

I guess it will vary between different species and it may be that strains of bacteria in our Western guts are different from the strains of the same species in the guts of say tribes in the Amazon.

Some may have more or less strains depending on their genome.

This article makes reference to the impact of different strains of the same species on the immune system.

https://www.sciencedaily.com/releases/2018/01/180111141738.htm

It seems that 0518 is a strain of Enterrococus gallinarum that they have actually named e gallinarum mrx 0518.

Important to remember that the data being prepared will also be provided to the FDA with a view to securing Breakthrough Therapy designation, which if good data, I think is very possible.

Thanks JB very interesting

I think Phil has answered your question

As no doubt Phil would explain

-4D have an extension library of different bacterial species taken from a wide variety of stool donors
-Using the Micro RX platform they are able to isolate different strains within the same bacterial species
-This is achieved by a multi - omics approach involving genome mining, transcriptomics, proteomics, comparative genomics and metabolomics.
-These strains present a high degree of variation. For example, the strain selected from the species Enterrococus Gallinarum as the basis of Mrx 0518 was shown to generate a much more potent form of the anti tumor agent flagellin compared to other strains in the same species.

Right you had your chance to ask a question or make a clear statement. You have chosen not to so back to the filter board with you.

Make a list of clear questions rather than vague senile ramblings otherwise shut up.

Sorry who is advocating selling?